On December 1, Gelonghui (603367.SH) announced that Chenxin Pharmaceutical () announced that the board of directors agreed to stop planning for the spin-off of the holding subsidiary Shandong Chenxin Fodu Pharmaceutical Co., Ltd. (“Fodu Pharmaceutical”) to the main board of the Shenzhen Stock Exchange, and agreed that Fodu Pharmaceutical should apply for listing on the National SME Share Transfer System (New Third Board). After listing, Fodu Pharmaceutical will seek an opportunity to go public on the Beijing Stock Exchange according to the future capital market environment and strategic development needs.
辰欣药业(603367.SH)：终止筹划控股子公司佛都药业分拆至深圳证券交易所主板上市并申请在新三板挂牌
Chenxin Pharmaceutical (603367.SH): Terminate plans to spin-off the holding subsidiary Fodu Pharmaceutical to list on the main board of the Shenzhen Stock Exchange and apply for listing on the new third board
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.